Elevated levels of BCAAs are often observed in individuals with obesity, diabetes, and metabolic syndrome, may via interfering with insulin signaling pathways.[27, 59, 60] The elevation of BCAAs in AGA patients may participate in the incidence of such metabolic comorbidities, and diet restriction of such BCAAs may exert benefit for the treatment AGA. This evidence concerns the gene INS and obesity disorder.